BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals today announced the initiation of patient treatments in a three-part Phase 1-2a clinical trial of ACY-1215, an oral Class II histone deacetylase (HDAC) inhibitor, in adults with relapsed and relapsed/refractory multiple myeloma. The Phase 1 dose-ranging study will evaluate ACY-1215 alone and in combination with bortezomib (Velcade®) and dexamethasone, a current standard of care for treatment of myeloma. Following identification of optimal combination dosing in Phase 1, the Phase 2a portion of the study will evaluate rate and duration of cancer response to ACY-1215 in combination with standard of care treatment to achieve proof-of-concept. Selective inhibition of the intracellular enzyme HDAC6 may provide enhanced anti-cancer effectiveness through potentially reduced side effects and improved tolerability compared to current non-selective inhibitors, which are active against both Class I and Class II HDACs. This clinical trial is being conducted by Acetylon with alliance support from The Leukemia & Lymphoma Society (LLS).
